Moderna, Inc. (MRNA) Operating Margin
- Operating margin · 12 months: Value -149.01%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -149.01% | Operating income / revenue. Period ending 2026-06-30. $-3.32B ÷ $2.23B × 100 ≈ -149.01% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -3.32B USD | Operating Income (Loss) |
| Revenue | 2.23B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.71B USD | Cost of Goods and Services Sold |
| Research and development | 2.88B USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-3.32B | $2.23B | $1.71B | $2.88B | (m) | -149.01% |
| 2026-03-31 | $-3.41B | $2.23B | $1.73B | $2.92B | (m) | -153.35% |
| 2025-12-31 | $-3.07B | $1.94B | $868.00M | $3.13B | (m) | -158.13% |
| 2025-09-30 | $-3.46B | $2.23B | $1.16B | $3.48B | (m) | -155.15% |
| 2025-06-30 | $-3.27B | $3.08B | $1.46B | $3.81B | (m) | -106.34% |
| 2025-03-31 | $-3.73B | $3.18B | $1.46B | $4.34B | (m) | -117.37% |
| 2024-12-31 | $-3.94B | $3.24B | $1.46B | $4.54B | (m) | -121.91% |
| 2024-09-30 | $-2.69B | $5.08B | $1.65B | $4.83B | (m) | -53.00% |
| 2024-06-30 | $-4.63B | $5.05B | $3.38B | $4.85B | (m) | -91.78% |
| 2024-03-31 | $-5.14B | $5.15B | $4.00B | $4.78B | (m) | -99.73% |
| 2023-12-31 | $-4.24B | $6.85B | $4.69B | $4.84B | (m) | -61.90% |
| 2023-09-30 | $-2.67B | $9.12B | $5.68B | $4.65B | (m) | -29.22% |
| 2023-06-30 | $513.00M | $10.65B | $4.54B | $4.31B | (m) | 4.82% |
| 2023-03-31 | $4.83B | $15.06B | $5.19B | $3.87B | (m) | 32.05% |
| 2022-12-31 | $9.42B | $19.26B | $5.42B | $3.29B | (m) | 48.90% |
| 2022-09-30 | $13.25B | $21.39B | $4.45B | $2.73B | (m) | 61.94% |
| 2022-06-30 | $15.64B | $23.00B | $4.07B | $2.43B | (m) | 68.02% |
| 2022-03-31 | $16.26B | $22.60B | $3.44B | $2.14B | (m) | 71.93% |
| 2021-12-31 | $13.30B | $18.47B | $2.62B | $1.99B | (m) | 71.98% |
| 2021-09-30 | $7.61B | $11.83B | $1.67B | $2.10B | (m) | 64.33% |
| 2021-06-30 | $3.82B | $7.02B | $950.93M | $1.93B | (m) | 54.39% |
| 2021-03-31 | $633.86M | $2.73B | $200.93M | $1.66B | (m) | 23.20% |
| 2020-12-31 | $-763.14M | $803.39M | $7.93M | $1.37B | (m) | -94.99% |
| 2020-09-30 | $-617.71M | $246.71M | (m) | $729.43M | (m) | -250.38% |
| 2020-06-30 | $-513.36M | $105.84M | (m) | $504.58M | (m) | -485.03% |
| 2020-03-31 | $-534.94M | $52.57M | (m) | $481.03M | (m) | -1017.52% |
| 2019-12-31 | $-545.72M | $60.21M | (m) | $496.31M | (m) | -906.38% |
| 2019-09-30 | $-569.66M | $81.58M | (m) | $529.22M | (m) | -698.32% |
| 2019-06-30 | $-524.62M | $106.29M | (m) | $518.55M | (m) | -493.59% |
| 2019-03-31 | $-477.70M | $122.05M | (m) | $494.53M | (m) | -391.38% |
| 2018-12-31 | $-413.27M | $135.07M | (m) | $454.08M | (m) | -305.97% |
| 2018-09-30 | $-302.06M | $191.55M | (m) | (m) | (m) | -157.69% |
| 2018-06-30 | $-284.12M | $192.27M | (m) | (m) | (m) | -147.77% |
| 2018-03-31 | $-281.30M | $204.54M | (m) | (m) | (m) | -137.53% |
| 2017-12-31 | $-269.36M | $205.82M | (m) | $410.46M | (m) | -130.87% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-223.77M | $108.40M | (m) | $274.72M | (m) | -206.44% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |